Bridgeway Capital Management, LLC Aim Immuno Tech Inc. Transaction History
Bridgeway Capital Management, LLC
- $4.44 Billion
- Q3 2024
A detailed history of Bridgeway Capital Management, LLC transactions in Aim Immuno Tech Inc. stock. As of the latest transaction made, Bridgeway Capital Management, LLC holds 11,000 shares of AIM stock, worth $2,530. This represents 0.0% of its overall portfolio holdings.
Number of Shares
11,000
Previous 88,900
87.63%
Holding current value
$2,530
Previous $32,000
93.75%
% of portfolio
0.0%
Previous 0.0%
Shares
10 transactions
Others Institutions Holding AIM
# of Institutions
36Shares Held
9.01MCall Options Held
0Put Options Held
0-
Armistice Capital, LLC New York, NY4.33MShares$995,9000.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.99MShares$457,4010.0% of portfolio
-
Black Rock Inc. New York, NY698KShares$160,6010.0% of portfolio
-
Geode Capital Management, LLC Boston, MA464KShares$106,7230.0% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il458KShares$105,2860.0% of portfolio
About AIM ImmunoTech Inc.
- Ticker AIM
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 48,049,300
- Market Cap $11.1M
- Description
- AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's products include Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome...